Inactivation of a multifunctional RNA-binding protein can lead to the acquisition of pro-metastatic phenotypes, possibly by stabilizing large-scale transcriptomic changes that provide a selective advantage during cancer progression.

The gluconeogenic enzyme PCK1 and pyrimidine nucleotide biosynthetic enzyme DHODH drive hypoxic pyrimidine nucleotide biosynthesis and liver metastatic colonization in colorectal cancer, which is therapeutically exploitable by DHODH pharmacologic inhibition.

Weakly migratory cancer cells facilitate their own escape from the primary tumor by releasing microvesicles that activate fibroblasts to remodel matrix and facilitate cancer cell metastasis.

DUX4 expression is a common feature of metastatic tumors, where it is significantly associated with immune cell exclusion, decreased objective response to immune checkpoint blockade, and reduced patient survival.

ctDNA predict prognosis and treatment response of mTNBC patients more sensitively than traditional tumor markers, which implies ctDNA may be valuable for individualized treatment decision-making and paves the way for a non-invasive real-time clinical management strategy in patients with mTNBC.

Integration of evolutionary dynamics framed through a mathematical model improved outcomes in abiraterone monotherapy for the treatment of metastatic castrate-resistant prostate cancer.

A photoconversion-based isolation technique enables systematic investigation of spatially distinct small metastases (microcolonies) versus large lesions (macrometastases).

Cancer stem cells that have undergone EMT are identified in the region surrounding metastatic human oral tumours in a retrospective cohort study, and these are predictive of metastatic outcome in an image-based machine learning approach.

Single-cell RNA sequencing of biopsy samples from advanced-stage lung cancer reveals tumor and immune cell features associated with response to immune checkpoint therapy.